• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five Forces Summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Other 1 o Market segments o Comparison by Other1 placement o Diabetes drugs - Market size and forecast 2019-2024 o hGH - Market size and forecast 2019-2024 o Thyroid hormone disorders - Market size and forecast 2019-2024 o Testosterone replacement therapy - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by Other1 • Customer landscape o Overview • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography • Drivers, Challenges, and Trends o Market drivers o Volume driver - Demand led growth o Volume driver - Supply led growth o Volume driver - External factors o Volume driver - Demand shift in adjacent markets o Price driver - Inflation o Price driver - Shift from lower to higher priced units o Market challenges o Market trends • Vendor Landscape o Overview o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Abbott Laboratories o AbbVie Inc. o AstraZeneca Plc o Eli Lilly and Co. o GlaxoSmithKline Plc o Groupe Sanofi o Merck & Co. Inc. o Novartis International AG o Novo Nordisk AS o Pfizer Inc. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibits • 1.Key Finding 1 • 2.Key Finding 2 • 3.Key Finding 3 • 4.Key Finding 4 • 5.Key Finding 5 • 6.Key Finding 6 • 7.Key Finding 7 • 8.Market in focus • 9.Parent market • 10.Market characteristics • 11.Product / Service portfolio of key vendors included in the market definition • 12.Market segments • 13.Global - Market size and forecast 2019 - 2024 ($ billion) • 14.Global market: Year-over-year growth 2019 - 2024 (%) • 15.Five forces analysis 2019 & 2024 • 16.Bargaining power of buyers • 17.Bargaining power of suppliers • 18.Threat of new entrants • 19.Threat of substitutes • 20.Threat of rivalry • 21.Market condition - Five forces 2019 • 22.Other1 placement - Market share 2019-2024 (%) • 23.Comparison by Other1 placement • 24.Diabetes drugs - Market size and forecast 2019-2024 ($ billion) • 25.Diabetes drugs - Year-over-year growth 2019-2024 (%) • 26.hGH - Market size and forecast 2019-2024 ($ billion) • 27.hGH - Year-over-year growth 2019-2024 (%) • 28.Thyroid hormone disorders - Market size and forecast 2019-2024 ($ billion) • 29.Thyroid hormone disorders - Year-over-year growth 2019-2024 (%) • 30.Testosterone replacement therapy - Market size and forecast 2019-2024 ($ billion) • 31.Testosterone replacement therapy - Year-over-year growth 2019-2024 (%) • 32.Others - Market size and forecast 2019-2024 ($ billion) • 33.Others - Year-over-year growth 2019-2024 (%) • 34. Market opportunity by Other1 • 35.Customer landscape • 36.Market share by geography 2019-2024 (%) • 37.Geographic comparison • 38.North America - Market size and forecast 2019-2024 ($ billion) • 39.North America - Year-over-year growth 2019-2024 (%) • 40.Europe - Market size and forecast 2019-2024 ($ billion) • 41.Europe - Year-over-year growth 2019-2024 (%) • 42.Asia - Market size and forecast 2019-2024 ($ billion) • 43.Asia - Year-over-year growth 2019-2024 (%) • 44.ROW - Market size and forecast 2019-2024 ($ billion) • 45.ROW - Year-over-year growth 2019-2024 (%) • 46.Key leading countries • 47.Market opportunity by geography ($ billion) • 48.Impact of drivers • 49.Impact of challenges • 50.Landscape disruption • 51.Industry risks • 52.Vendors covered • 53.Market positioning of vendors • 54.Abbott Laboratories - Overview (1/3) • 55.Abbott Laboratories - Overview (2/3) • 56.Abbott Laboratories - Overview (3/3) • 57.Abbott Laboratories - Business segments • 58.Abbott Laboratories - Key offerings • 59.Abbott Laboratories - Key customers • 60.Abbott Laboratories - Segment focus • 61.AbbVie Inc. - Overview (1/3) • 62.AbbVie Inc. - Overview (2/3) • 63.AbbVie Inc. - Overview (3/3) • 64.AbbVie Inc. - Business segments • 65.AbbVie Inc. - Key offerings • 66.AbbVie Inc. - Key customers • 67.AbbVie Inc. - Segment focus • 68.AstraZeneca Plc - Overview (1/3) • 69.AstraZeneca Plc - Overview (2/3) • 70.AstraZeneca Plc - Overview (3/3) • 71.AstraZeneca Plc - Product and service • 72.AstraZeneca Plc - Key offerings • 73.AstraZeneca Plc - Key customers • 74.AstraZeneca Plc - Segment focus • 75.Eli Lilly and Co. - Overview (1/3) • 76.Eli Lilly and Co. - Overview (2/3) • 77.Eli Lilly and Co. - Overview (3/3) • 78.Eli Lilly and Co. - Business segments • 79.Eli Lilly and Co. - Key offerings • 80.Eli Lilly and Co. - Key customers • 81.Eli Lilly and Co. - Segment focus • 82.GlaxoSmithKline Plc - Overview (1/3) • 83.GlaxoSmithKline Plc - Overview (2/3) • 84.GlaxoSmithKline Plc - Overview (3/3) • 85.GlaxoSmithKline Plc - Business segments • 86.GlaxoSmithKline Plc - Key offerings • 87.GlaxoSmithKline Plc - Key customers • 88.GlaxoSmithKline Plc - Segment focus • 89.Groupe Sanofi - Overview (1/3) • 90.Groupe Sanofi - Overview (2/3) • 91.Groupe Sanofi - Overview (3/3) • 92.Groupe Sanofi - Business segments • 93.Groupe Sanofi - Key offerings • 94.Groupe Sanofi - Key customers • 95.Groupe Sanofi - Segment focus • 96.Merck & Co. Inc. - Overview (1/3) • 97.Merck & Co. Inc. - Overview (2/3) • 98.Merck & Co. Inc. - Overview (3/3) • 99.Merck & Co. Inc. - Business segments • 100.Merck & Co. Inc. - Key offerings • 101.Merck & Co. Inc. - Key customers • 102.Merck & Co. Inc. - Segment focus • 103.Novartis International AG - Overview (1/3) • 104.Novartis International AG - Overview (2/3) • 105.Novartis International AG - Overview (3/3) • 106.Novartis International AG - Business segments • 107.Novartis International AG - Key offerings • 108.Novartis International AG - Key customers • 109.Novartis International AG - Segment focus • 110.Novo Nordisk AS - Overview (1/3) • 111.Novo Nordisk AS - Overview (2/3) • 112.Novo Nordisk AS - Overview (3/3) • 113.Novo Nordisk AS - Business segments • 114.Novo Nordisk AS - Key offerings • 115.Novo Nordisk AS - Key customers • 116.Novo Nordisk AS - Segment focus • 117.Pfizer Inc. - Overview (1/3) • 118.Pfizer Inc. - Overview (2/3) • 119.Pfizer Inc. - Overview (3/3) • 120.Pfizer Inc. - Business segments • 121.Pfizer Inc. - Key offerings • 122.Pfizer Inc. - Key customers • 123.Pfizer Inc. - Segment focus • 124.Currency conversion rates for US$ • 125.Research Methodology • 126.Validation techniques employed for market sizing • 127.Information sources • 128.List of abbreviations

Abbott Laboratories AbbVie Inc. AstraZeneca Plc Eli Lilly and Co. GlaxoSmithKline Plc Groupe Sanofi Merck & Co. Inc. Novartis International AG Novo Nordisk AS Pfizer Inc.